XML 17 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) - USD ($)
$ in Thousands
Total
Series Seed
Series A
Series B
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2020 [1]   13,174,805 16,836,436 22,164,724        
Beginning balance at Dec. 31, 2020   $ 5,494 $ 27,067 $ 75,857        
Ending balance (in shares) at Mar. 31, 2021 [1]   13,174,805 16,836,436 22,164,724        
Ending balance at Mar. 31, 2021   $ 5,494 $ 27,067 $ 75,857        
Beginning balance (in shares) at Dec. 31, 2020 [1]         33,069,513      
Beginning balance at Dec. 31, 2020 $ (29,721)       $ 1 $ 600 $ 3 $ (30,325)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Stock-based compensation expense 1,336         1,336    
Other comprehensive income (loss) (1)           (1)  
Net loss (8,409)             (8,409)
Ending balance (in shares) at Mar. 31, 2021 [1]         33,069,513      
Ending balance at Mar. 31, 2021 $ (36,795)       $ 1 1,936 2 (38,734)
Beginning balance (in shares) at Dec. 31, 2021   0 0 0        
Beginning balance at Dec. 31, 2021   $ 0 $ 0 $ 0        
Ending balance (in shares) at Mar. 31, 2022 0 0 0 0        
Ending balance at Mar. 31, 2022   $ 0 $ 0 $ 0        
Beginning balance (in shares) at Dec. 31, 2021         124,303,083      
Beginning balance at Dec. 31, 2021 $ 363,576       $ 12 444,388 (184) (80,640)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of common stock upon exercise of vested stock options (in shares) 153,570       153,570      
Issuance of common stock upon exercise of vested stock options $ 156         156    
Stock-based compensation expense 2,110         2,110    
Other comprehensive income (loss) (370)           (370)  
Net loss (15,763)             (15,763)
Ending balance (in shares) at Mar. 31, 2022         124,456,653      
Ending balance at Mar. 31, 2022 $ 349,709       $ 12 $ 446,654 $ (554) $ (96,403)
[1] (1)    The shares of the Company’s common and redeemable convertible preferred stock, prior to the Business Combination (as defined in Note 1) have been retroactively restated to reflect the exchange ratio of approximately 3.6281 established in the Business Combination as described in Note 3.